Last reviewed · How we verify

NCT05936073: DELTADESCRIBE

DELTA DESCRIBE: the French Collaborative Project

Recruiting now Last updated 28 May 2025
What this trial tests

trial testing Patients co-infected HBV/HDV in Hepatitis D in 734 participants. Currently enrolling.

Timeline
22 January 2024
Primary endpoint
22 June 2025
22 June 2025

Quick facts

Lead sponsorUniversity Hospital, Limoges
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment734
Start date22 January 2024
Primary completion22 June 2025
Estimated completion22 June 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Limoges

Who can join

18 and older, any sex, with Hepatitis D. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our global objective is to draw up a photograph of HDV patients over one year in metropolitan France and identify the barriers of screening and care. The investigator suspects a mismatch between HBV and HDV screening, the first step for specialized care pathway in metropolitan France.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Delta Describe, the French Collaborative Project: The Profile and Management of Hepatitis Delta Patients in Metropolitan France.
    Bosselut M, Carrier P, Brichler S, Alain S, et al · · 2026 · PMID 42043213 · DOI 10.3390/v18040424

Verify or expand the search:

Other recruiting trials for Hepatitis D

Currently open trials in the same condition.

Other University Hospital, Limoges trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05936073.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing